The "TGFb inhibitors – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. The companies and academics are working to assess challenges and seek ...

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting ...

Transforming growth factor (TGF)-β signaling is an attractive therapeutic target as it is deregulated in many cancers. But challenges remain around developing inhibitors that can specifically block ...

Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 ...

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on ...

A mouse study suggests that using an inhibitor of transforming growth factor beta (TGF-beta) alongside primary therapy for cancer has clinical benefits, reducing metastases and radiation side effects.

AVID200 is a novel, rationally designed, highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms ...

Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications.

By revealing that the TGF-beta pathway plays a protective role against uterine cancer, this work has significantly advanced our understanding of the disease and opened novel avenues for future ...

In contrast to the physiological role of TGF-β that regulates cell growth and differentiation, the authors find that circulating, pathological levels of TGF-β activate a SMAD3 signaling pathway ...